Antifungal therapy of murine Aspergillus terreus infection

Antimicrobial Agents and Chemotherapy

Volumn 48, Issue 10, 2004, Pages 3715-3719

  Graybill, John R ^a   Hernandez, Steve ^a   Bocanegra, Rosie ^a   Najvar, Laura K ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; POSACONAZOLE;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS TERREUS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; SURVIVAL; TISSUE CULTURE; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ANTIFUNGAL AGENTS; ASPERGILLOSIS; MALE; MICE; MICE, INBRED ICR; NEUTROPENIA; SURVIVAL;

EID: 4644351585     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.48.10.3715-3719.2004     Document Type: Article

References (25)

1. Adam, O., A. Aupérin, F. Wilquin, J. Bourhis, B. Gachot, and E. Chachaty. 2004. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin. Infect. Dis. 38:917-920.
2. Arikan, S., M. Lozano-Chiu, V. Paetznick, S. Nangia, and J. H. Rex. 1999. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J. Clin. Microbiol. 37:3946-3951.
3. Bowman, J. C., G. K. Abruzzo, J. W. Anderson, A. M. Flattery, C. J. Gill, V. B. Pikounis, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481.
4. Bowman, J. C., P. S. Hicks, M. B. Kurtz, H. Rosen, D. M. Schmatz, P. A. Liberator, and C. M. Douglas. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. 46:3001-3012.
5. Denning, D. 1998. Invasive aspergillosis. Clin. Infect. Dis. 26:781-785.
6. Denning, D. W., K. Venkateswarlu, K. L. Oakley, M. J. Anderson, N. J. Manning, D. A. Stevens, D. W. Warnock, and S. L. Kelly. 1997. Itraconazole resistance in Aspergillus fumigatus. Antimicrob. Agents Chemother. 41:1364-1368.
7. Einsele, H., H. Holger, G. Roller, J. Löffler, I. Rothenhöfe, C. A. Müller, et al. 1997. Detection and identification of fungal pathogens in blood by using molecular probes. J. Clin. Microbiol. 35:1353-1360.
8. Espinel-Ingroff, A. 2001. Germinated and nongerminated conidial suspensions for testing of susceptibilities of Aspergillus spp. to amphotericin B, itraconazole, posaconazole, ravuconazole, and voriconazole. Antimicrob. Agents Chemother. 45:605-607.
9. Herbrecht, R., D. W. Denning, T. F. Patterson, J. E. Bennett, R. E. Greene, J.-W. Oestman, W. V. Kern, K. A. Marr, P. Ribaud, J. Lortholary, R. Sylvester, R. H. Rubin, J. Wingard, P. Stark, C. Durand, D. Caillot, E. Thiel, P. H. Chandrasekar, M. Hodges, H. Schlamm, P. F. Troke, and B. E. DePauw. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Engl. J. Med. 347:408-415.
10. Iwen, P., M. Rupp, A. Langnas, E. Reed, and S. Hinrichs. 1998. Invasive pulmonary aspergillosis due to Aspergillus terreus: 12-year experience and review of the literature. Clin. Infect. Dis. 26:1092-1097.
11. Kurtz, M. B., I. B. Heath, J. Marrinan, S. Dreikorn, J. Onishi, and C. Douglas. 1994. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1, 3)-β-D-glucan synthase. Antimicrob. Agents Chemother. 38:1480-1489.
12. Lass-Flörl, C., G. Kofler, G. Kropshofer, J. Hermans, A. Kreczy, M. P. Dierich, and D. Niederwieser. 1998. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis. J. Antimicrob. Chemother. 42:497-502.
13. Mellinghoff, I. K., D. J. Winston, G. Mukwaya, and G. J. Schiller. 2002. Treatment of Scedosporium apiospermum brain abscesses with posaconazole. Clin. Infect. Dis. 34:1648-1650.
14. Murphy, M., E. M. Bernard, T. Ishimuri, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
15. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; approved standard. NCCLS document M38-A. NCCLS, Wayne, Pa.
16. Paterson, P. J., S. Seaton, H. G. Prentice, and C. C. Kibbler. 2003. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J. Antimicrob. Chemother. 52:873-876.
17. Petraitis, V., R. Petraitiene, A. A. Sarafandi, A. M. Kelaher, C. A. Lyman, H. E. Casler, T. Sein, A. H. Groll, J. Bacher, N. A. Avila, and T. J. Walsh. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843.
18. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
19. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, and P. G. Sentry. 2002. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob. Agents Chemother. 46:1032-1037.
20. Sponsel, W. E., J. R. Graybill, H. L. Nevarez, and D. Dang. 2002. Ocular and systemic posaconazole (SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br. J. Ophthalmol. 86:829-830.
21. Sugar, A. M., and X. P. Liu. 2001. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob. Agents Chemother. 45:601-604.
22. Sun, Q. N., L. K. Najvar, R. Bocanegra, D. Loebenberg, and J. R. Graybill. 2002. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob. Agents Chemother. 46:2310-2312.
23. Sutton, D. A., S. E. Sanche, S. G. Revankar, A. W. Fothergill, and M. G. Rinaldi. 1999. In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus, with a head-to-head comparison to voriconazole. J. Clin. Microbiol. 37:2343-2345.
24. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
25. Walsh, T. J., V. Petraitis, R. Petraitiene, A. Field-Ridley, D. Sutton, M. Ghannoum, T. Sein, R. Schaufele, J. Peter, J. Bacher, H. Casler, D. Armstrong, A. Espinel-Ingroff, M. G. Rinaldi, and C. A. Lyman. 2003. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J. Infect. Dis. 188:305-319.